CAS Number: 183133-96-2
Therapeutic Category
Anti-Cancer/ Oncology
API Technology
Synthetic
Dose Form
Injectable
Available Regulatory Filing
USA
Australia
Russia
Malaysia
Europe
Canada
Innovator Brand (USA)
JEVTANA
Mechanism of Action
Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.
Indication
JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.